CFTR and cystic fibrosis: The pharmacokinetics of statins may be altered in people with CF receiving CFTR modulator therapy, given the potential OATP1B1/3 inhibitory activity of elexacaftor and BCRP inhibitory activity of elexacaftor and ivacaftor [10].